Vietnam Newsletter - May 2025
- thuyvo6
- Jun 20
- 2 min read

Market Summary
In May 2025, the Vietnamese market witnessed transactions totaling around c.USD359m. Notably, the consumer and retail, and healthcare sectors were prominently involved:
The consumer and retail sector featured a notable transaction where UOB invested in Bien Hoa Consumer.
The healthcare sector featured Livzon investing USD219m in Imexpharm, a manufacturer and distributor of pharmaceutical products.
Aggregate Deals Value = c.USD359m
This month's top deals
Consumer and retail
Singapore's UOB Venture Management invests in Vietnam's Bien Hoa Consumer JSC
UOB Venture Management (UOBVM) has acquired a 12% stake in Bien Hoa Consumer JSC (BHC) to support its expansion and future IPO. The investment will enhance distribution, fund a high-tech manufacturing facility, and strengthen BHC’s presence across 69 countries. UOBVM sees Vietnam as a key market, aligning with its long-term, sustainable investment strategy.
Article link:
Singapore's UOB Venture Management invests in Vietnam's Bien Hoa Consumer JSC
Healthcare & Life Science
China's Livzon buys 65% in Vietnam's Imexpharm for over USD219 million
China’s Livzon Pharmaceutical Group has acquired a 64.81% stake in Vietnam’s Imexpharm Corporation for approximately USD219 million via its subsidiary LIAN SGP HOLDING PTE, becoming Imexpharm’s largest shareholder. The acquisition includes shares previously held by SK Investment, Binh Minh Kim Investment JSC, and KBA Investment JSC, while Vietnam Pharmaceutical Corporation retains a 22.04% stake. Livzon aims to use this acquisition to expand its footprint in Southeast Asia, adding to its existing global presence across over 30 countries.
Article link:
China's Livzon buys 65% in Vietnam's Imexpharm for over USD219 million
Note: Deal values include disclosed announced & closed deals with amounts restricted to the local scene i.e., amounts related to the Vietnam entity and/or business. Rumored deals are not included. Cross-posted deals are also adjusted to avoid double counting.
Comments